Adjuvant Trials
1. Double Blind Placebo Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
| ClinicalTrials.gov Identifier |
NCT02273375 |
This study is currently active, not recruiting.
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
Alberta
Cross Cancer Institute, Edmonton
Tom Baker Cancer Centre, Calgary
Newfoundland & Labrador
Dr H Bliss Murphy Cancer Centre, St John's
Nova Scotia
QE II Health Sciences Centre, Halifax
Ontario
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Lakeridge Health, Oshawa
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste Marie
Niagara Health System, St Catherines
Health Sciences North, Sudbury
Thunder Bay Regional Health Science Centre, Thunder Bay
Mount Sinai Hospital, Toronto, ON
Princess Margaret Hospital, University Health Network, Toronto
Quebec
McGill University Oncology Department, Montreal
Saskatchewan
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
2. Study Of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects with Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected NSCLC (CANOPY-A)
| ClinicalTrials.gov Identifier |
NCT03447769 |
This study is currently recruiting.
The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
Alberta
Edmonton
New Brunswick
Moncton
Ontario
3. AZD9291 Versus Placebo in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma, Folowing Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
| ClinicalTrials.gov Identifier |
NCT02511106 |
This study is active but not currently recruiting.
A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
New Brunswick
Moncton
Ontario
Brampton